The study by Gill et al1 suggested a higher risk of adverse outcomes including syncope, bradycardia, pacemaker insertions, and hip fractures in community-dwelling adults with dementia receiving cholinesterase inhibitors compared with well-matched controls. These findings have important implications, as the agents in question remain the mainstay of symptomatic treatment for an otherwise debilitating illness.
Chan M. Adverse Events in Patients Receiving Cholinesterase Inhibitors Due to Dissimilar Follow-up Periods. Arch Intern Med. 2009;169(18):1718-1725. doi:10.1001/archinternmed.2009.347